GIMBE - News Cliniche - Pagina 4

Home

News Cliniche - Pagina 4

ONLINE IL SITO GIMBE SULL'EMERGENZA COVID-19

News Cliniche

GIMBE: Eventi, progetti, pubblicazioni e altre attività istituzionali della Fondazione GIMBE
Metodologiche: articoli pertinenti le aree del know-how GIMBE, pubblicati nei top-six journals*
Cliniche: articoli di ricerca clinica primaria e secondaria pubblicati nei top-six journals*
Sanità: notizie dalla sanità italiana
Eventi: congressi, conferenze, workshop nazionali e internazionali relativi alle aree del know-how GIMBE

*N Engl J Med, Lancet, Ann Intern Med, JAMA, BMJ, PLos Med

1 dicembre 2012

Antimicrobial catheters for reduction of symptomatic urinary tract infection in adults requiring short-term catheterisation in hospital: a multicentre randomised controlled trial

Lancet 2012;380:1927-1935

Comprehensive self management and routine monitoring in chronic obstructive pulmonary disease patients in general practice: randomised controlled trial

BMJ 2012;345:e7642

The spectrum of thyroid disease and risk of new onset atrial fibrillation: a large population cohort study

BMJ 2012;345:e7895

Cardiovascular mortality after pre-eclampsia in one child mothers: prospective, population based cohort study

BMJ 2012;345:e7677

Prognosis in women with interval breast cancer: population based observational cohort study

BMJ 2012;345:e7536

29 novembre 2012

Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome

N Engl J Med 2012;367:2089-2099

Bedside Monitoring to Adjust Antiplatelet Therapy for Coronary Stenting

N Engl J Med 2012;367:2100-2109

27 novembre 2012

The Long-Term Health Consequences of Child Physical Abuse, Emotional Abuse, and Neglect: A Systematic Review and Meta-Analysis

PLoS Med 9(11): e1001349

24 novembre 2012

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

Lancet 2012;380:1819-1828

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

Lancet 2012;380:1829-1839

2

3

4

5

6

Pagina aggiornata il 13/06/2026